SCHEMBL5015909

SCHEMBL5015909

Cc1ccc(NC(=O)Nc2cccc(CN3CCN(C(=O)O)C[C@@H]3C)c2F)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 2/20 0.40
DHODH Q02127 1/20 0.40
MAPK10 P53779 7/20 0.40
MAPK8 P45983 6/20 0.40
NPSR1 Q6W5P4 1/20 0.39
PIK3R1 P27986 1/20 0.37
MTOR P42345 1/20 0.37
FPR1 P21462 1/20 0.37
FPR2 P25090 1/20 0.37
CCR3 P51677 2/20 0.36
HTT P42858 1/20 0.36
MAPK9 P45984 1/20 0.36
CSNK1E P49674 1/20 0.36
OGA O60502 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ROCK2 O75116 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5014984 1.00 RORC (0.40) RORCDHODHMAPK10MAPK8NPSR1
SCHEMBL4246553 1.00 RORC (0.40) RORCDHODHMAPK10MAPK8NPSR1
SCHEMBL4246655 0.94 FPR1 (0.42) RORCDHODHMAPK10MAPK8NPSR1
SCHEMBL4246650 0.94 FPR1 (0.42) RORCDHODHMAPK10MAPK8NPSR1
SCHEMBL4239756 0.92 FPR1 (0.40) RORCDHODHMAPK10MAPK8NPSR1
SCHEMBL4239754 0.92 FPR1 (0.40) RORCDHODHMAPK10MAPK8NPSR1
SCHEMBL2250542 0.92 MAPK10 (0.39) RORCDHODHMAPK10MAPK8NPSR1
SCHEMBL4791219 0.92 MAPK10 (0.40) RORCDHODHMAPK10MAPK8NPSR1
SCHEMBL4237998 0.89 GPR119 (0.39) RORCDHODHMAPK10MAPK8NPSR1
SCHEMBL4238002 0.89 GPR119 (0.39) RORCDHODHMAPK10MAPK8NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1962852-A2 COMPOUNDS, COMPOSITIONS AND METHODS Cytokinetics, Inc. (US) 2008-09-03 EP claimed
US-20070197497-A1 Compounds, compositions and methods CYTOKINETICS, INC. 2007-08-23 US claimed
WO-2007078839-A2 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INC. (US) 2007-07-12 WO claimed
EP-1962852-B1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS INC (US) 2017-01-25 EP disclosed
EP-1962852-A2 COMPOUNDS, COMPOSITIONS AND METHODS Cytokinetics, Inc. (US) 2008-09-03 EP disclosed
US-20070197497-A1 Compounds, compositions and methods CYTOKINETICS, INC. 2007-08-23 US disclosed
WO-2007078839-A2 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INC. (US) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197497-A1 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 RORC 3759/4885DHODH 3768/4885MAPK10 2521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.